NO20076468L - Injiserbare sammensetninger og fremgangsmate for fremstilling av slike sammensetninger - Google Patents

Injiserbare sammensetninger og fremgangsmate for fremstilling av slike sammensetninger

Info

Publication number
NO20076468L
NO20076468L NO20076468A NO20076468A NO20076468L NO 20076468 L NO20076468 L NO 20076468L NO 20076468 A NO20076468 A NO 20076468A NO 20076468 A NO20076468 A NO 20076468A NO 20076468 L NO20076468 L NO 20076468L
Authority
NO
Norway
Prior art keywords
compositions
methods
preparing
cox
inhibitor
Prior art date
Application number
NO20076468A
Other languages
English (en)
Inventor
Rajesh Jain
Chand Kour Jindal
Sukhjeet Singh
Sanjay Boldhane
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of NO20076468L publication Critical patent/NO20076468L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det beskrives ny og meget stabile farmasøytiske sammensetninger omfattende i det minste en syklooksygenase II enzym (COX-II) inhibitor eller ikke-steroidale antiinflammatoriske medikament (NSAID) eller COX/LOX inhibitor, eller dets tautomere former, analoger, isomerer, polymorger, solvater, prodrug eller salter derav som aktive ingredienser egnet for parenteral administrering, fortrinnsvis via intramuskulær (IM) eller intravenøs (IV) rute; fremgangsmåter for å fremstille slike sammensetninger og terapeutiske metoder for anvendelse av slike sammensetninger tilveiebringes. De analgetiske og antiinflammatoriske injiserbare sammensetninger i følge oppfinnelsen er svært nyttige i pattedyr, spesielt i mennesker, for behandling av akutte smertefulle tilstander så som en eller flere av postoperativt traume, smerte assosiert med cancer, idrettskader, migrene hodepine, nevrologisk smerte og smerte assosiert med isjias og spondylitt og lignende, og/eller kroniske smertefulle tilstander, og/eller tilhørende forstyrrelser så som inflammasjon, feber, allergi eller lignende.
NO20076468A 2005-05-27 2007-12-14 Injiserbare sammensetninger og fremgangsmate for fremstilling av slike sammensetninger NO20076468L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1357DE2005 2005-05-27
PCT/IN2006/000177 WO2006126214A2 (en) 2005-05-27 2006-05-25 Injectable compositions and process for preparation of such compositions

Publications (1)

Publication Number Publication Date
NO20076468L true NO20076468L (no) 2008-02-27

Family

ID=36917368

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076468A NO20076468L (no) 2005-05-27 2007-12-14 Injiserbare sammensetninger og fremgangsmate for fremstilling av slike sammensetninger

Country Status (15)

Country Link
EP (1) EP1895983A2 (no)
JP (1) JP2008542260A (no)
KR (1) KR20080016689A (no)
CN (1) CN101217939A (no)
AU (1) AU2006250765A1 (no)
BR (1) BRPI0611170A2 (no)
CA (1) CA2609242A1 (no)
CR (1) CR9616A (no)
EA (1) EA200702646A1 (no)
MX (1) MX2007014862A (no)
NO (1) NO20076468L (no)
RS (1) RS20070461A (no)
TN (1) TNSN07482A1 (no)
WO (1) WO2006126214A2 (no)
ZA (1) ZA200711068B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2728785T3 (es) 2007-09-07 2019-10-28 United Therapeutics Corp Soluciones tampón con actividad bactericida selectiva contra las bacterias gramnegativas y métodos para usarlas
KR20140014350A (ko) * 2009-03-12 2014-02-06 큠버랜드 파마슈티컬즈 인코포레이티드 정맥 내 투여용 이부프로펜의 투여
US8871810B2 (en) 2009-07-15 2014-10-28 Cumberland Pharmaceuticals Inc. Treating critically ill patients with intravenous ibuprofen
CN102335114B (zh) * 2010-07-23 2015-07-15 重庆医药工业研究院有限责任公司 一种稳定的布洛芬精氨酸注射剂及其制备方法
CN102370615B (zh) * 2010-08-19 2013-09-04 四川科伦药物研究有限公司 一种布洛芬注射制剂及其制备方法
JP6051466B2 (ja) 2011-10-18 2016-12-27 ラクオリア創薬株式会社 医薬組成物
CN102512383A (zh) * 2011-12-25 2012-06-27 天津市嵩锐医药科技有限公司 供注射用的帕瑞昔布钠药物组合物
US9072710B2 (en) 2012-03-16 2015-07-07 Cumberland Pharmaceuticals Inc. Injectable ibuprofen formulation
CN103372216B (zh) * 2012-04-26 2015-05-06 北京京卫燕康药物研究所有限公司 一种含有塞来昔布的固体药物组合物
TWI646091B (zh) 2012-12-28 2019-01-01 日商衛斯克慧特股份有限公司 鹽類及晶形
US20140187635A1 (en) 2012-12-28 2014-07-03 Themis Medicare Limited Diclofenac compositions
US20140275261A1 (en) 2013-03-15 2014-09-18 Dr. Reddy's Laboratories, Inc. Diclofenac parenteral compositions
CN103263385B (zh) * 2013-05-17 2016-04-27 江苏正大清江制药有限公司 一种塞来昔布长效纳米注射剂及其制备方法
KR20170099911A (ko) * 2014-12-20 2017-09-01 트로이카 파마슈티칼스 리미티드 파라세타몰 주사 제제
WO2016170401A1 (en) * 2015-04-20 2016-10-27 Umedica Laboratories Pvt. Ltd Novel injectable composition of diclofenac sodium
CN107303266B (zh) * 2016-04-18 2020-09-08 重庆润泽医药有限公司 左旋奥拉西坦注射液及其制备方法
CN107303264A (zh) * 2016-04-18 2017-10-31 重庆润泽医药有限公司 无泡沫左旋奥拉西坦注射液及其制备方法
FR3077984B1 (fr) * 2018-02-16 2020-02-21 Vetoquinol Sa Composition multiusage de torasemide
CN109498852B (zh) * 2018-12-29 2022-06-24 广州噢斯荣医药技术有限公司 治疗骨科疾病的生物降解材料及其应用
CN111103381A (zh) * 2019-12-25 2020-05-05 南京希麦迪医药科技有限公司 一种液质联用测定人血浆中尼美舒利浓度的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5389681A (en) * 1992-10-22 1995-02-14 Ciba-Geigy Corporation Parenteral solutions for diclofenac salts
IT1283252B1 (it) * 1996-03-15 1998-04-16 Pulitzer Italiana Soluzioni di piroxicam iniettabili per via parenterale
IN187306B (no) * 1998-01-12 2002-03-23 Panacea Biotec Ltd
PE20021017A1 (es) * 2001-04-03 2002-11-24 Pharmacia Corp Composicion parenteral reconstituible
AU2003249510A1 (en) * 2002-08-12 2004-02-25 Ranbaxy Laboratories Limited A parenteral dosage form of selective cox-2 inhibitors

Also Published As

Publication number Publication date
WO2006126214A2 (en) 2006-11-30
CN101217939A (zh) 2008-07-09
WO2006126214A3 (en) 2007-06-07
EA200702646A1 (ru) 2008-06-30
KR20080016689A (ko) 2008-02-21
JP2008542260A (ja) 2008-11-27
AU2006250765A1 (en) 2006-11-30
TNSN07482A1 (fr) 2009-03-17
CR9616A (es) 2008-10-30
BRPI0611170A2 (pt) 2010-08-17
MX2007014862A (es) 2008-02-21
RS20070461A (en) 2008-11-28
ZA200711068B (en) 2009-03-25
CA2609242A1 (en) 2006-11-30
EP1895983A2 (en) 2008-03-12

Similar Documents

Publication Publication Date Title
NO20076468L (no) Injiserbare sammensetninger og fremgangsmate for fremstilling av slike sammensetninger
CY1122336T1 (el) Eνωσεις πυρρολιου ως αναστολεις πρωτεϊνικων κινασων εrκ και φαρμακευτικες συνθεσεις που περιεχουν αυτες τις ενωσεις
DK1742624T3 (da) Dopamin-agonist-kombinationsterapi med sedativer til forbedring af søvnkvalitet
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
CL2011000101A1 (es) Compuestos derivados de piridazina sustituida; inhibidores de la señalizacion hedgehog y smo; composicion farmaceutica; y uso para el tratamiento de trastornos o sindromes asociados con enfermedades hiperproliferativas.
MX2009002893A (es) Tratamiento de trastornos hepaticos mediante la administracion de conjugados de la proteina asociada al receptor (rap).
DK1970059T3 (da) Lægemiddel med calciumdobesilat til behandling og profylakse af senelidelser
NO20060424L (no) 5-heteroringbaserte P38 kinaseinhibitorer
DK1505973T3 (da) Kombinationer til behandling af multipelt myelom
CY1110495T1 (el) Χρηση ενος αγωνιστη υποδοχεα nmda για τη θεραπεια εμβοης που προκαλειται απο κοχλιακη διεγερτοτοξικοτητα
ECSP077421A (es) Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1
NO20051726L (no) Pyrimidinonderivaer som terapeutiske midler ovenfor akutte og kroniske inflammasjons-, iskemiske og remodeleringsprosesser
MX2010002278A (es) Farmacos antivirales para el tratamiento de una infeccion por arenavirus.
BR112013026202A2 (pt) composições e usos terapêuticos de inibidores quinase epsilon relacionado a ikk e quinase i de ligação a tank
ATE456565T1 (de) Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren
SV2009003283A (es) Inhibidores de la actividad de la akt
EA200802166A1 (ru) Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью
AR060836A1 (es) Un disco trans-mucosa para administrar un agente activo, una composicion trans-mucosa y el metodo de administracion obtenido
ATE489371T1 (de) Benzamidglucokinaseaktivatoren
DK1781596T3 (da) Aminosyreafledte profarmaka af propofolsammensætninger og anvendelser deraf
DK1981851T3 (da) Kinaseinhibitorer og fremgangsmåder til anvendelse deraf
WO2007143557A3 (en) Compounds and methods for treating mammalian gastrointestinal parasitic infections
EA200901237A1 (ru) Применение димирацетама при лечении хронической боли
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
BRPI0415538A (pt) utilização de um derivado do pirazol para o preparo de medicamento úteis na prevenção e no tratamento das dislipidemias e das doenças associadas às dislipidemias e/ou à obesidade

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application